Plant Compound Oxypaeoniflorin Blocks Liver Inflammation in Alcohol-Related Disease
Oxypaeoniflorin suppresses alcohol-induced liver damage by targeting TEAD4-driven pyroptosis, revealing a novel herbal hepatoprotective mechanism.
Summary
Oxypaeoniflorin (Opae), a natural compound derived from peony root, significantly reduced liver damage in a mouse model of alcohol-associated liver disease. The compound works by suppressing a specific transcription factor called TEAD4, which normally drives expression of NLRP3 — a key inflammasome protein that triggers a destructive form of cell death called pyroptosis. Using RNA sequencing and genetic silencing experiments, researchers confirmed that TEAD4 directly binds to the NLRP3 promoter, making it a central regulator of liver inflammation in alcohol injury. Opae also inhibited pyroptosis in immune cells called macrophages, and protective signals from those treated macrophages further shielded liver cells from alcohol damage. These findings position Opae as a promising natural candidate for treating or preventing alcohol-related liver disease.
Detailed Summary
Alcohol-associated liver disease (ALD) is a major and growing cause of liver-related morbidity and mortality worldwide, yet effective pharmacological treatments remain limited. Identifying natural compounds that can interrupt the inflammatory cascades driving ALD progression is therefore a meaningful research priority with direct healthspan implications.
This study investigated oxypaeoniflorin (Opae), a bioactive monoterpene glycoside found in Paeonia lactiflora (peony root), a herb used in traditional Chinese medicine. Researchers established an in vivo ALD model in mice using chronic Lieber-DeCarli ethanol-containing liquid diets and combined this with genetic silencing of TEAD4 to map the molecular pathway through which Opae acts.
Opae treatment markedly reduced markers of alcoholic liver injury and was associated with significant downregulation of phosphorylated YAP1, TEAD1, and TEAD4 — components of the Hippo signaling pathway. Crucially, expression of NLRP3 and IL-1β, proteins central to the inflammasome-driven pyroptotic cell death pathway, was also substantially suppressed. RNA sequencing implicated a NOD-like receptor/mitophagy/Hippo signaling axis as the regulatory core. Dual-luciferase reporter assays directly confirmed that TEAD4 binds the NLRP3 promoter, establishing a transcriptional link between Hippo pathway dysregulation and NLRP3-mediated pyroptosis. Both siRNA and shRNA silencing of TEAD4 in cells and mice, respectively, independently reproduced the anti-inflammatory effects of Opae.
Beyond hepatocytes, Opae also suppressed pyroptosis in LPS-stimulated macrophages, and conditioned medium from these treated macrophages protected primary hepatocytes from ethanol-induced injury — highlighting a paracrine hepatoprotective mechanism.
These results suggest Opae could be developed as a therapeutic agent targeting TEAD4-NLRP3 pyroptosis in ALD. Caveats include the preclinical mouse model, abstract-only access, and the need for pharmacokinetic and human translational studies.
Key Findings
- Oxypaeoniflorin significantly reduced alcohol-induced liver damage in a chronic mouse ALD model.
- TEAD4 directly binds the NLRP3 promoter, transcriptionally driving pyroptosis in alcohol-exposed liver cells.
- Silencing TEAD4 alone — without Opae — was sufficient to suppress NLRP3 and reduce liver inflammation.
- Opae inhibited pyroptosis in macrophages, and those treated macrophages sent protective signals to hepatocytes.
- RNA sequencing identified the NOD-like receptor/mitophagy/Hippo axis as the core hepatoprotective network.
Methodology
Researchers used a chronic Lieber-DeCarli ethanol liquid diet mouse model of ALD combined with hepatic TEAD4 shRNA silencing in vivo and siRNA silencing in AML-12 hepatocyte cell lines. Mechanistic validation employed RNA sequencing, dual-luciferase reporter assays, and conditioned medium transfer experiments using LPS-stimulated mouse peritoneal macrophages.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. All data are preclinical (mouse and cell models), and translation to human ALD requires clinical validation. Pharmacokinetics, bioavailability, and optimal dosing of oxypaeoniflorin in humans have not been established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: